Skip to main content

Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the quarter ended 30 September 2025 (Q3 2025). All figures are in USD unless stated otherwise. Q3 2025 HighlightsQ3 2025 unaudited group revenue of approximately $206 million, up 53% year-over-year. FY 2025 revenue guidance increased to $800 million to $820 million1. Gozellix® now fully reimbursed by Centers for Medicare and Medicaid Services (CMS): Level II HCPCS2 code and Transitional Pass-Through (TPT) payment status effective 1 October 20253. Illuccix® now approved in 19 European markets4 and the United Kingdom (UK); commercial launch has commenced in the UK, Germany, France, Finland, Sweden, Norway and Denmark.  First...

Continue reading

September 2025 Quarter Results

PERTH, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) — Paladin Energy Ltd (ASX:PDN, TSX:PDN, OTCQX:PALAF) (“Paladin” or the “Company”) advises that it has released its quarterly activities report for the three month period ended 30 September 2025 (“September 2025 Quarter Results”). The Company has also released an accompanying presentation on the September 2025 Quarter Results. The quarterly activities report and presentation are available on Paladin’s website (https://www.paladinenergy.com.au/investors/asx-announcements/). For further information contact:Investor RelationsHead Office Paula RaffoPaladin Investor Relations T: +61 8 9423 8100E: paula.raffo@paladinenergy.com.auCanadaBob HemmerlingPaladin Investor Relations T: +1 250-868-8140E: Bob.Hemmerling@paladinenergy.caMediaHead OfficeAnthony HasluckPaladin Corporate AffairsT:...

Continue reading

Rocky Mountain Chocolate Factory Reports Second Quarter Fiscal 2026 Financial Results

Management to Host Conference Call Tomorrow at 9:00 a.m. Eastern Time DURANGO, Colo., Oct. 13, 2025 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we”, “RMCF”, or “Rocky Mountain Chocolate”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is reporting financial and operating results for its second quarter of fiscal 2026, which ended August 31, 2025. “We’ve taken meaningful steps to transform and modernize our business and are beginning to see early signs of progress,” said Jeff Geygan, Interim CEO of the Company. “During the quarter, we focused on strengthening our operations and laying the groundwork for scalable growth. Our ERP and POS systems are providing us with clearer insight into store performance and customer...

Continue reading

Michelin adjusts outlook for 2025 financial year

                                                          Clermont-Ferrand – October 13, 2025 – 5:50pm COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Michelin adjusts outlook for 2025 financial year Based on fresh Q3 financial results which reflect further deterioration of the business environment versus expectations made in July, Michelin group has decided to adjust the outlook for 2025, ahead of the Q3 sales release planned on October 22. Besides North America, Michelin has posted year-on-year volume growth in the third quarter, which demonstrates the ability to drive growth and value across the various market segments, in a chaotic business context and despite near-term uncertainties weighing on demand of B2C and B2B customers. However, the North American business deteriorated more sharply than expected: Q3 sales volume decreased...

Continue reading

Dragonfly Energy Announces Third Quarter 2025 Select Preliminary Results

Preliminary Third Quarter Net Sales and Adjusted EBITDA Exceeded our Guidance Preliminary Third Quarter Net Sales Represent 26% Year over Year Growth RENO, Nev., Oct. 13, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today announced preliminary third quarter 2025 Net Sales and Adjusted EBITDA. The Company anticipates third quarter 2025 Net Sales of $16.0 million and Adjusted EBITDA of $(2.2) million, above guidance of $15.9 million for Net Sales and above guidance of $(2.7) million for Adjusted EBITDA. Anticipated results represent 26% year-over-year growth in Net Sales and an approximately $3.3 million reduction in Adjusted EBITDA loss. “Preliminary third quarter Net Sales and Adjusted EBITDA exceeded our...

Continue reading

Immuron Q1 FY26 YoY growth

Sales Highlights (unaudited):Global • Q1 sales AUD$2.0 million up 34% on prior comparative period (pcp)     Australia • Q1 sales AUD$1.6 million up 52% on pcp     Canada • Q1 sales AUD$0.0 million down 92% on pcp     USA • Q1 sales AUD$0.4 million up 44% on pcpMELBOURNE, Australia, Oct. 13, 2025 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract.Continued growth (+34% on pcp) in Australia can be contributed to: (1) increased awareness and consideration driven by extensive digital and social media marketing. (2) same store...

Continue reading

Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook

Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2025 Qualitative Update: Tecan reports mid-single-digit local currency growth in the third quarter and confirms full-year 2025 outlook Männedorf, Switzerland, October 13, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today provided a qualitative update on its performance for the third quarter of 2025.Sales for the third quarter increased by a mid-single-digit percentage in local currencies, representing a further sequential improvement after a mid-single-digit decline in Q1 and a low-single-digit decline in Q2. At the segment level, the Life Sciences Business recorded a low-single-digit sales decline and the Partnering Business achieved a sales increase in the low teens percentage range, both in local currencies and in line with expectations....

Continue reading

THEON plans to acquire 9.8% stake in Exosens

PRESS RELEASE Bloomberg (THEON:NA) / Reuters (THEON.AS)11 October 2025 – Theon International Plc (THEON) has entered into a definitive agreement with HLD Europe SCA, Invest Prince Henri SCA and Invest Gamma Sarl, investment companies belonging to Groupe HLD (HLD), to purchase a 9.8% stake in Exosens SA (EXOSENS) for a cash consideration of €268.7 million corresponding to €54.0 per share. EXOSENS is a leading French company specializing in advanced electro-optical technologies, including light amplification, detection and imaging systems. Following the completion of the transaction, THEON will become the second largest shareholder in EXOSENS, after Groupe HLD. The closing of the transaction remains subject to regulatory notifications in a selectednumber of countries, and is expected to take place in early Q1 2026. In connection with the...

Continue reading

Solitron Devices, Inc. Announces Fiscal 2026 Second Quarter Results

WEST PALM BEACH, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) — Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2026 second quarter results.  FISCAL 2026 SECOND QUARTER HIGHLIGHTS –Net sales increased 11% to approximately $3.99 million in the fiscal 2026 second quarter versus $3.58 million in the fiscal 2025 second quarter. Net bookings increased 147% to $4.32 million in the fiscal 2026 second quarter versus $1.75 million in the prior year second quarter. Backlog increased 146% to $18.64 million at the end of the fiscal 2026 second quarter as compared to $7.57 million at the end of the fiscal 2025 second quarter. Net income (loss) was ($0.23) million, or ($0.11) per share, for the fiscal 2026 second quarter versus net income of $0.02 million, or $.01 per share, for the fiscal 2025 second...

Continue reading

Hingham Savings Reports Third Quarter 2025 Results

HINGHAM, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) — HINGHAM INSTITUTION FOR SAVINGS (NASDAQ: HIFS), Hingham, Massachusetts announced results for the quarter ended September 30, 2025. Earnings Net income for the quarter ended September 30, 2025 was $17,295,000 or $7.93 per share basic and $7.85 per share diluted, as compared to $5,846,000 or $2.68 per share basic and $2.66 per share diluted for the same period last year. The Bank’s annualized return on average equity for the third quarter of 2025 was 15.15%, and the annualized return on average assets was 1.54%, as compared to 5.52% and 0.54% for the same period last year. Net income per share (diluted) for the third quarter of 2025 increased by 195.1% compared to the same period in 2024. Core net income for the quarter ended September 30, 2025, which represents net income excluding...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.